# Ajax Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ajax-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.ajaxtherapeutics.com/
- Total disclosed funding: $95M
- Latest round: Series C (Apr 26, 2024)
- Investors on record: 9

## About

Based in New York, US, and founded in 2019 by co-founders Ross Levine MD, Olli Silvennoinen, and Martin Vogelbaum (CEO), Ajax Therapeutics, Inc. operates as a provider of next-generation JAK2 inhibitors and targeted therapies for hematologic cancers to pharmaceutical companies and oncology research institutions. In April 2024, Ajax Therapeutics, Inc. raised USD 95 million in Series C funding led by Goldman Sachs Alternatives, with participation from Eli Lilly & Company, Vivo Capital, RA Capital Management, Point72, EcoR1 Capital, Boxer Capital, Schrödinger, Inc., and Inning One Ventures.

The company provides a wide range of therapeutic solutions, such as selective Type II JAK2 inhibitors for hematologic cancers, including myeloproliferative neoplasms (MPNs).

## Funding rounds

- Series C, Apr 26, 2024, $95M — Vivo Capital, Goldman Sachs Asset Management, Schrodinger, LLC, Eli Lilly & Company, RA Capital Management, EcoR1 Capital, Point72 Asset Management, Inning One Ventures, Boxer Capital

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series C
- Schrodinger, LLC — Series C
- Eli Lilly & Company — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Point72 Asset Management — Series C
- Inning One Ventures (https://capitalatlas.ai/funds/inning-one-ventures) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C